Abstract
Purpose: The effects of multidisciplinary team (MDT) discussion intervention on the treatment and prognosis of advanced colorectal cancer (CRC) are still controversial. Large sample size studies to evaluate the efficacy in patients with advanced CRC are lacking. Materials and Methods: We statistically analyzed the data of surgical patients diagnosed with advanced CRC from 2008 to 2014 by retrospective analysis. Patients were divided into two groups according to whether or not they received MDT intervention. After at least 3 years of follow-up, differences between two groups were compared with respect to treatment process and patient prognosis. Results: The time to treatment in the intervention group was shorter (9.6 ± 4.2 days vs 10.7 ± 5.6 days; p= 0.002). Multivariate survival analysis suggested that MDT intervention reduced the risk of death (HR = 0.677; p = 0.006). It had significant interaction with tumor invasion and tumor stage, particularly showing beneficial effects in the tumor stage IV subgroup (p=0.005) and tumor invasion T4 subgroup (p<0.001). Conclusion: MDT intervention accelerated the treatment process and reduced the death risk of patients with advanced CRC, especially improving the overall survival of stage IV and invasion T4 patients.
Introduction
Colorectal cancer (CRC) remains a leading cause of global cancer-related mortality. While therapeutic pathways for early-stage CRC are well-established, advanced cases—characterized by lymph node involvement or distant metastasis—present significant clinical complexity. Traditionally, treatment decisions for these patients were often managed by a single attending physician, relying on personal experience and general guidelines.
The Multidisciplinary Team (MDT) model was introduced to address this complexity by integrating expertise from surgery, oncology, radiology, and pathology into a unified, personalized treatment plan. Despite its theoretical benefits, the impact of MDTs on patient prognosis has been a subject of debate. Some critics argue that the logistical coordination required for MDTs might inadvertently delay treatment. This study provides large-scale clinical evidence to clarify the impact of MDT interventions on the survival and treatment efficiency of patients with advanced CRC.
Methods
This study utilized a retrospective analysis of 879 patients diagnosed with Stage III or IV CRC at Sun Yat-Sen University (specifically the First and Seventh Affiliated Hospitals) between 2008 and 2014. Patients were followed through December 2017, ensuring at least three years of follow-up data for all participants.
The cohort was divided into two groups:
- MDT Group (n=473): Treatment plans were formulated during weekly multidisciplinary meetings.
- Non-MDT Group (n=406): Treatment plans were determined by a single physician following standard clinical guidelines.
To account for potential confounding variables such as age, gender, and tumor characteristics, the researchers employed multivariate Cox proportional hazard models. This statistical approach ensured that observed survival benefits could be more confidently attributed to the MDT process itself.
Results
Treatment Efficiency
Contrary to concerns that committee-based decision-making might slow clinical workflows, the MDT group demonstrated a significantly shorter "Time to Treatment" (TTT). The average time from admission to the start of treatment was 9.6 days for the MDT group compared to 10.7 days for the non-MDT group (p=0.002). This suggests that MDTs can act as workflow accelerators by streamlining diagnostic reviews and surgical scheduling.
Survival Outcomes
The primary finding of the study was a significant improvement in overall survival for patients receiving MDT intervention. Multivariate analysis identified MDT intervention as an independent protective factor, reducing the risk of death by approximately 32% (Hazard Ratio = 0.677; p = 0.006).
Subgroup Analysis: The "Complexity Benefit"
The survival advantage provided by MDT discussions was not uniform across all patient types but was most pronounced in the most severe cases. Specifically, significant survival benefits were observed in:
- Tumor Stage IV: Patients with distant metastasis (p=0.005).
- Tumor Invasion T4: Patients where the tumor had grown through the wall of the organ (p<0.001).
Interestingly, the MDT group initially contained a higher proportion of T4 stage patients (80.5% vs 12.8% in the non-MDT group), indicating that clinicians were already triaging more complex cases to the MDT. Despite this higher baseline risk, these patients achieved superior adjusted survival outcomes.
Discussion and Conclusion
The findings demonstrate that MDT intervention significantly improves the prognosis for patients with advanced CRC, particularly those with high-risk features like T4 invasion or Stage IV disease. Furthermore, the MDT approach improves clinical efficiency by reducing the time to treatment. There were no significant differences in recurrence or metastasis rates, suggesting the MDT's primary impact is on overall survival management.
While the study is limited by its retrospective nature and the potential for selection bias, the results strongly support the integration of MDTs into standard care for advanced CRC. Future work should focus on prospective, randomized trials to establish standardized MDT protocols across diverse healthcare systems. In conclusion, clinical characteristics such as tumor invasion and stage should be primary considerations when determining the necessity of MDT discussions to maximize patient survival.
Summary updated